Clinical Trial Update: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a PARP inhibitor combined with a CTLA-4 blocker in BRCA-deficient ovarian cancer, including fallopian tube and peritoneal ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Neoplasms

Drugs mentioned

• CTLA-4 inhibitor (unspecified)
• PARP inhibitor (unspecified)

Snippet

Sponsor: New Mexico Cancer Research Alliance | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING